$14.91
+5.35 (+55.96%)
Open$9.16
Previous Close$9.56
Day High$14.92
Day Low$9.16
52W High$101.25
52W Low$3.18
Volume—
Avg Volume9.82M
Market Cap12.32M
P/E Ratio—
EPS$-25.77
SectorBiotechnology
Analyst Ratings
Strong Sell
6 analysts
Price Target
+106.4% upside
Current
$14.91
$14.91
Target
$30.77
$30.77
$21.48
$30.77 avg
$35.71
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 18.39M | 59.60M | 759.7K |
| Net Income | -1,407,587,770 | -4,105,084,228 | -24,634 |
| Profit Margin | -7,652.8% | -7,270.1% | -3.2% |
| EBITDA | -1,182,760,510 | -3,641,032,030 | -38,889 |
| Free Cash Flow | — | — | -29,815 |
| Rev Growth | -69.1% | -69.1% | +6.1% |
| Debt/Equity | — | — | 0.67 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $210.39 | -0.18% | 88.1 | 372.39B |
| AMGN | Amgen Inc | $326.31 | -2.95% | 23.0 | 179.23B |
| GILD | Gilead Sciences Inc | $129.58 | -1.88% | 17.4 | 160.50B |
| VRTX | Vertex Pharmaceuticals Inc | $436.95 | -2.99% | 26.4 | 114.32B |
| REGN | Regeneron Pharmaceuticals | $698.25 | -2.05% | 16.7 | 73.89B |
| ALNY | Alnylam Pharmaceuticals Inc | $286.98 | -2.20% | 66.6 | 38.43B |